STOCK TITAN
  1. Home
  2. Sec-filings
  3. HQY
  4. [Form 4] HEALTHEQUITY, INC. Insider Trading Activity

HealthEquity (HQY) director sells 2,439 shares in 10b5-1 trade

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

HEALTHEQUITY, INC. director Gayle Furgurson exercised stock options and sold shares in a pre-planned transaction. She exercised options to acquire 2,439 shares of common stock at an exercise price of $47.21 per share, then sold 2,439 shares in an open-market transaction at $90.00 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on January 14, 2026, indicating they were pre-scheduled. Following the transactions, she holds 19,733 shares of HealthEquity common stock directly, and the exercised option covering 2,439 shares is now fully used.

Positive

  • None.

Negative

  • None.
Insider Wellborn Gayle Furgurson
Role null
Sold 2,439 shs ($220K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 2,439 $0.00 --
Exercise Common Stock 2,439 $47.21 $115K
Sale Common Stock 2,439 $90.00 $220K
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct, null); Common Stock — 22,172 shares (Direct, null)
Footnotes (1)
  1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, 2026. The option is immediately exercisable.
Shares sold 2,439 shares Open-market sale of common stock on May 28, 2026 at $90.00
Sale price $90.00 per share Price for 2,439 common shares sold on May 28, 2026
Shares exercised 2,439 shares Stock option exercise for common stock on May 28, 2026
Exercise price $47.21 per share Exercise price of stock option for 2,439 shares
Post-transaction holdings 19,733 shares Common stock directly owned after transactions
Option expiration August 1, 2027 Original expiration date of exercised stock option
Net share direction -2,439 shares Net buy/sell shares in transaction summary (net-sell)
Rule 10b5-1 trading plan regulatory
"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
derivative exercise/conversion financial
"transaction_action": "derivative exercise/conversion""
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 regulatory
"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wellborn Gayle Furgurson
(Last)(First)(Middle)
C/O HEALTHEQUITY, INC.
15 W. SCENIC POINTE DR., STE. 100
(Street)
DRAPER UTAH 84020
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
HEALTHEQUITY, INC. [ HQY ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/28/2026M(1)2,439A$47.2122,172D
Common Stock05/28/2026S(1)2,439D$9019,733D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$47.2105/28/2026M(1)2,439 (2)08/01/2027Common Stock2,439$00D
Explanation of Responses:
1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 14, 2026.
2. The option is immediately exercisable.
Remarks:
The Power of Attorney given by Ms. Wellborn was previously filed with the U.S. Securities and Exchange Commission on June 26, 2023, as an exhibit to a statement on Form 4 filed by Ms. Wellborn with respect to HealthEquity, Inc. and is hereby incorporated by reference.
/s/ Delano Ladd, Attorney-in-Fact06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did HealthEquity (HQY) director Gayle Furgurson report?

Director Gayle Furgurson reported exercising stock options and selling shares of HealthEquity common stock. She exercised options for 2,439 shares and sold 2,439 shares in an open-market transaction, all recorded on May 28, 2026 in this Form 4 filing.

How many HealthEquity (HQY) shares did the director sell and at what price?

She sold 2,439 shares of HealthEquity common stock at a price of $90.00 per share. This sale was categorized as an open-market or private transaction and was part of a broader exercise-and-sell sequence disclosed in the Form 4.

What stock options did the HealthEquity (HQY) director exercise in this Form 4?

She exercised a stock option covering 2,439 shares of HealthEquity common stock at an exercise price of $47.21 per share. The option was immediately exercisable and, after this transaction, the option position referenced in the filing shows zero remaining shares.

How many HealthEquity (HQY) shares does the director hold after these transactions?

Following the reported transactions, Gayle Furgurson directly holds 19,733 shares of HealthEquity common stock. This reflects her position after exercising options for 2,439 shares and selling 2,439 shares on the same date, as summarized in the Form 4.

Was the HealthEquity (HQY) director’s sale under a Rule 10b5-1 trading plan?

Yes. The footnotes state the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on January 14, 2026. Such plans pre-schedule trades, meaning the timing of the May 28, 2026 sale was established in advance by the director.

Does the HealthEquity (HQY) Form 4 show remaining stock options for the director?

The derivative section reports a stock option for 2,439 shares that was fully exercised, leaving zero shares following the transaction. The derivative summary is empty after this exercise, indicating no remaining unexercised derivative position is shown in this particular filing.